Crinetics Pharmaceuticals (CRNX)

KSIX Media Holdings, Inc., Mar Ked Mineral Exploration, Inc., NORTH AMERICAN ENERGY RESOURCES, INC., North American Energy Resources, Inc., Surge Holdings, Inc.

SEC CIK

0001658247

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CRNX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$73.00

Low target

$55.00

High target

$91.00

Citizens Capital Markets

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

27 Feb 25

8-K

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

24 Feb 25

8-K

Regulation FD Disclosure

14 Jan 25

8-K

Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health

10 Jan 25

8-K

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

16 Dec 24

8-K

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

12 Nov 24

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results

12 Nov 24

Transcripts

View all

CRNX

Earnings call transcript

2024 Q4

27 Feb 25

CRNX

Earnings call transcript

2024 Q3

12 Nov 24

CRNX

Earnings call transcript

2024 Q2

8 Aug 24

CRNX

Earnings call transcript

2024 Q1

9 May 24

CRNX

Earnings call transcript

2023 Q4

28 Feb 24

CRNX

Earnings call transcript

2020 Q4

31 Mar 21

Latest ownership filings

View all

Richard Scott Struthers

WELLINGTON MANAGEMENT GROUP LLP

Notice of proposed sale of securities

Financial summary

Financial statements Chart CRNX financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	265.85 mm	265.85 mm	265.85 mm	265.85 mm	265.85 mm	265.85 mm
Cash burn (monthly)	17.57 mm	(no burn)	31.58 mm	28.24 mm	21.56 mm	18.83 mm
Cash used (since last report)	36.56 mm	n/a	65.69 mm	58.74 mm	44.84 mm	39.17 mm
Cash remaining	229.29 mm	n/a	200.15 mm	207.11 mm	221.00 mm	226.68 mm
Runway (months of cash)	13.0	n/a	6.3	7.3	10.3	12.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CRNX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	243	234	+3.8%
Opened positions	36	28	+28.6%
Closed positions	27	29	-6.9%
Increased positions	109	95	+14.7%
Reduced positions	65	73	-11.0%

13F shares	Current	Prev Q	Change
Total value	4.59 tn	3.87 tn	+18.6%
Total shares	101.06 mm	86.22 mm	+17.2%
Total puts	11.70 k	44.20 k	-73.5%
Total calls	26.10 k	23.30 k	+12.0%
Total put/call ratio	0.4	1.9	-76.4%

Largest owners	Shares	Value	Change
Vanguard	9.09 mm	$464.74 bn	+44.6%
FMR	8.93 mm	$456.49 bn	+100.4%
BlackRock	7.52 mm	$384.25 bn	+14.7%
Wellington Management	6.95 mm	$355.38 bn	+55.9%
Driehaus Capital Management	6.14 mm	$313.99 bn	+4.3%
T. Rowe Price	5.41 mm	$276.84 mm	+9.5%
EcoR1 Capital	4.29 mm	$219.25 bn	0.0%
Farallon Capital Management	4.08 mm	$208.36 bn	+250.7%
STT State Street	2.99 mm	$152.92 bn	+5.4%
JHG Janus Henderson	2.80 mm	$142.90 bn	+15.1%

Largest transactions	Shares	Bought/sold	Change
FMR	8.93 mm	+4.47 mm	+100.4%
Farallon Capital Management	4.08 mm	+2.91 mm	+250.7%
Vanguard	9.09 mm	+2.80 mm	+44.6%
Wellington Management	6.95 mm	+2.49 mm	+55.9%
BlackRock	7.52 mm	+965.25 k	+14.7%
Paradigm Biocapital Advisors	1.91 mm	-605.92 k	-24.1%
Perceptive Advisors	184.53 k	-540.17 k	-74.5%
SG Americas Securities	542.45 k	+529.48 k	+4084.6%
UBS UBS	707.73 k	+524.84 k	+287.0%
Point72 Asset Management	2.79 mm	+488.30 k	+21.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Feb 25	Struthers Richard Scott	Common Stock	Grant	Acquire A	No	No	0	89,000	0.00	346,485
20 Feb 25	Struthers Richard Scott	Stock Option Common Stock	Grant	Acquire A	No	No	36.86	313,000	11.54 mm	313,000
20 Feb 25	Dana Pizzuti	Common Stock	Grant	Acquire A	No	No	0	43,000	0.00	74,748
20 Feb 25	Dana Pizzuti	Stock Option Common Stock	Grant	Acquire A	No	No	36.86	65,000	2.40 mm	65,000
20 Feb 25	Stephen F. Betz	Common Stock	Grant	Acquire A	No	No	0	43,000	0.00	114,358
20 Feb 25	Stephen F. Betz	Stock Option Common Stock	Grant	Acquire A	No	No	36.86	65,000	2.40 mm	65,000
20 Feb 25	Jeff E. Knight	Common Stock	Grant	Acquire A	No	No	0	43,000	0.00	94,653
20 Feb 25	Jeff E. Knight	Stock Option Common Stock	Grant	Acquire A	No	No	36.86	65,000	2.40 mm	65,000
3 Feb 25	Dana Pizzuti	Common Stock	Sell	Dispose S	No	Yes	39.07	5,000	195.35 k	31,748
3 Feb 25	Dana Pizzuti	Common Stock	Option exercise	Acquire M	No	No	16.89	5,000	84.45 k	36,748